Jazz Pharmaceuticals (JAZZ) analyst forecast and price target
Analyst forecast
Consensus of 21 analyst ratings
Based on 12 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Needham | Maintained | Buy | $310.00 from $292.00 | Aug 26, 2026 |
| Truist Securities | Maintained | Buy | $281.00 from $264.00 | Aug 26, 2026 |
| Morgan Stanley | Maintained | Overweight | $322.00 from $283.00 | Aug 26, 2026 |
| Deutsche Bank | Maintained | Buy | $300.00 from $287.00 | Aug 26, 2026 |
| Morgan Stanley | Maintained | Overweight | $283.00 from $280.00 | Aug 11, 2026 |
| Baird | Maintained | Outperform | $280.00 from $252.00 | Aug 4, 2026 |
| Barclays | Maintained | Overweight | $270.00 from $260.00 | Aug 4, 2026 |
| Needham | Maintained | Buy | $292.00 from $282.00 | Aug 4, 2026 |
| Piper Sandler | Maintained | Overweight | $310.00 from $301.00 | Aug 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $280.00 from $245.00 | Aug 4, 2026 |
| Wells Fargo | Maintained | Overweight | $300.00 from $285.00 | Aug 4, 2026 |
| TD Cowen | Maintained | Buy | $300.00 from $275.00 | Aug 4, 2026 |
| Truist Securities | Maintained | Buy | $264.00 from $254.00 | Aug 4, 2026 |
| JP Morgan | Maintained | Overweight | $276.00 from $265.00 | Aug 4, 2026 |
| Needham | Maintained | Buy | $282.00 from $255.00 | Jul 20, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $290.00 | Jul 17, 2026 |
| Barclays | Maintained | Overweight | $260.00 from $253.00 | Jul 14, 2026 |
| Wells Fargo | Maintained | Overweight | $285.00 from $265.00 | Jul 14, 2026 |
| Deutsche Bank | Maintained | Buy | $270.00 from $250.00 | Jul 9, 2026 |
| Truist Securities | Maintained | Buy | $254.00 from $256.00 | Jul 7, 2026 |
Frequently asked questions
What is the price target for JAZZ stock?
The average 12-month analyst price target for Jazz Pharmaceuticals (JAZZ) is $295.50, with a high estimate of $322.00 and a low of $270.00, across 12 analysts.
Is JAZZ a buy, sell, or hold?
Analysts covering Jazz Pharmaceuticals currently average a Buy rating: 19 buy, 2 hold and 0 sell, from 21 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for JAZZ?
The average price target of $295.50 implies 17.14% upside from the last price of $252.27.
What is the latest analyst rating on JAZZ?
On Aug 26, 2026, Needham maintained Jazz Pharmaceuticals at Buy with a price target of $310.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.